FDA Would Let Distributed Manufacturers Register Once

FDA's registration rules assume a drug factory is a place. On 13 July 2026 the agency proposed to accommodate the case where it is a network: a proposed rule that would let a “distributed manufacturing establishment” — one quality unit at a hub, interchangeable manufacturing units wherever demand is — register with FDA once, as a single establishment.

The hub and the spokes

The proposal defines its subject with more precision than the phrase “distributed manufacturing” usually gets. A DME runs physical manufacturing at distributed manufacturing units — DMUs — at one or more geographic locations, the “spokes”. The units are “equivalent in design and operation”, manufacture the same drug or drugs, and sit under the oversight of a single quality unit at the “hub”, operating one unified pharmaceutical quality system. Units can be added, removed, or relocated as demand moves — including mobile units built to deploy quickly, the notice says, “in response to need (e.g., during an emergency)”.

The definition is also a fence. FDA considered whether other multi-site models — several contract manufacturers hired to make the same drug in different places — should get the streamlined pathway, and concluded they are unlikely to be appropriate for it. Distinct organizations with distinct quality systems are not one establishment, however similar their output.

What the pathway changes

Under the current rules, the notice concedes, the hub — if it manufactures — and every DMU would each register as separate establishments “even though they operate collectively as one establishment”. The proposal inverts that: one registration for the DME, with the churn of the model — a unit added here, removed there, a mobile unit relocated — handled as expedited updates to the existing registration, with timing rules written for units that move. Registration categories otherwise mirror what traditional manufacturers already file.

FDA's stated aim is to “decrease the regulatory burden for industry” while still getting timely establishment information. The rulemaking is issued in part under the FRAME initiative — CDER's Framework for Regulatory Advanced Manufacturing Evaluation, running since 2019 — and the preamble makes the supply-chain argument explicitly: units in a diverse range of geographic areas “can improve supply chain resiliency”, and pooled data across equivalent units can carry the validation strategy when a new unit is added or an existing one moves.

The half about foreign establishments

The proposal's second purpose has nothing to do with hubs or spokes. Section 2511 of the PREVENT Pandemics Act amended section 510(i) of the FD&C Act to require registration by foreign establishments that manufacture, prepare, propagate, compound, or process a drug imported into the United States — regardless of whether the drug undergoes further processing at a separate foreign establishment before import. The same clarification reaches drug listing. The proposed rule writes both into part 207.

That closes a visibility gap with real enforcement consequences: the upstream foreign site whose output is finished elsewhere before shipment. FDA's stated case for the change is supply-chain visibility and its ability “to prevent the importation of drugs that do not comply with current good manufacturing practice (CGMP) requirements or are otherwise adulterated or misbranded”. The economic analysis expects the statutory clarification to increase compliance among covered foreign establishments — which is a polite way of saying some establishments covered since the statute changed have not been registering.

Numbers and dates

• 11 September 2026: comments close, on both the rule and its information-collection burden. Docket FDA-2025-N-6075.
• Effective date: FDA proposes 30 calendar days after publication of any final rule, and asks for comment on that too.
• Cost: estimated annualized net costs of roughly $534,000 to $664,000, primary estimate $583,958 at a seven percent discount rate — mostly reading the rule, updating FDA's own systems, and newly registering foreign firms. The Office of Information and Regulatory Affairs calls the action significant under Executive Order 12866.

What is not settled

Everything — this is a proposal. The definitions, the expedited-update mechanics for mobile units, and the effective date are all open for comment until 11 September. What the proposal does not do is change CGMP expectations or the approval pathway for any product made this way: it is a registration rule. A manufacturer weighing the hub-and-spoke model still has to bring the quality system that makes “equivalent in design and operation” true — the registration paperwork was never the hard part, and FDA proposing to simplify it does not make it so.